This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Emisphere Technologies, Inc.
Drug Names(s): oral insulin
Description: This is an oral formulation of insulin using Emisphere’s oral drug delivery technology platform, known as the eligen technology. The technology uses proprietary, synthetic chemical compounds, known as EMISPHERE delivery agents, or “carriers.” These molecules facilitate or enable the transport of the therapeutic macromolecules across biological membranes. The delivery agents have no known pharmacological activity themselves. Emisphere’s eligen technology makes it possible to orally deliver a therapeutic molecule without altering its chemical form or biological integrity.
Oral Insulin News
Pink Sheet FDA's NDA And BLA Approvals: Fiasp, Ascor
Additional information available to subscribers only: